Capricor Therapeutics (CAPR) Operating Leases (2021 - 2026)

Capricor Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• In Q1 2026, Operating Leases rose 3322.65% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (up 3322.65% YoY), while the FY2025 annual figure was $14.3 million, up 2223.55% from the prior year.
• Operating Leases was $13.9 million for Q1 2026 at Capricor Therapeutics, down from $14.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $14.4 million in Q3 2025 to a low of $194603.0 in Q2 2025.
• Historically, Operating Leases has averaged $3.6 million across 5 years, with a median of $1.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Leases tumbled 81.36% in 2025, then jumped 3322.65% in 2026.
• A 5-year view of Operating Leases shows it stood at $1.9 million in 2022, then fell by 20.83% to $1.5 million in 2023, then sank by 58.55% to $616315.0 in 2024, then jumped by 2223.55% to $14.3 million in 2025, then declined by 2.63% to $13.9 million in 2026.
• The last three Operating Leases figures came in at $13.9 million (Q1 2026), $14.3 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.